Webinars

 
 

The FDA is now accepting In Vitro cardiotoxicity screening results from human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) for investigational new drugs. Mature hiPSC-CMs are preferred in order to translate in vitro results to the adult human heart. Here we will review the use of StemBioSys’ human cell-derived extracellular matrix (ECM) CELLvo™ Matrix Plus for rapid and robust hiPSC-CM maturation using high throughput screening plates (96 well). Additionally, we will review the use of mature hiPSC-CMs for repeated measures of electrophysiological function via genetically encoded calcium indicator (GCaMP6). Repeated measures enable the ability to test the chronic effects of drugs on hiPSC-CM structure and function. Some medications can cause delayed onset toxicity that can only be measured in vitro using repeated measures. Data shows the utility of mature hiPSC-CM in vitro assays to determine toxicity occurring over the course of four days with measurements of intracellular calcium flux and monolayer confluence.

Drs. Todd Herron, Travis Block and Andre Montiero Da Rocha present data from their experiments and introduce an innovative new tool for working with human cardiomyocytes.

Title provided for identification purposes only. The views and opinions expressed are those of the individual only and do not necessarily reflect the positions of the University of Michigan. Drs. Herron and Da Rocha are paid consultants to StemBioSys and have a small equity stake in the company.

Part 2 of 3: Choosing the right substrate – Culturing iPS-CMs on Extracellular Matrix Products with an emphasis on CELLvo™ Matrix Plus.

Title provided for identification purposes only. The views and opinions expressed are those of the individual only and do not necessarily reflect the positions of the University of Michigan. Drs. Herron and Da Rocha are paid consultants to StemBioSys and have a small equity stake in the company.

Part 1 of 3 in the StemBioSys Webinar Series: Choosing the right cell… iPS-CM vs. Adult Primary Cardiomyocytes, an overview.

Title provided for identification purposes only. The views and opinions expressed are those of the individual only and do not necessarily reflect the positions of the University of Michigan. Drs. Herron and Da Rocha are paid consultants to StemBioSys and have a small equity stake in the company.

The benefits of the unique CELLvo™ Matrix, the only natural cell culture substrate, will be discussed. The webinar describes the current challenges in removing cells from their native tissue and culturing them in a completely foreign environment such as tissue culture plastic.
Drs. Travis Block and Todd Herron discuss CELLvo Matrix Plus for cardiomyocyte maturation.